Position of an international panel of lung cancer experts on the decision for expansion of approval for pembrolizumab in advanced non-small-cell lung cancer with a PD-L1 expression level of ≥1% by the USA Food and Drug Administration. (3rd September 2019) - Mountzios, G; Remon, J; Novello, S; Blais, N; Califano, R; Cufer, T; Dingemans, A M; Liu, S V; Peled, N; Pennell, N A; Reck, M; Rolfo, C; et al.